The development of P-cadherin anticancer therapy commenced with PF-03732010, a humanized anti-CDH3 monoclonal antibody (mAb) with demonstrated antitumor activity confirmed by carcinoma mouse models [6]. The gene discussed is CDH3; the disease is carcinoma.